Subsequent Events (Details Narrative) (Collaboration and License Agreement with Janssen Biotech, Inc (Janssen), USD $) In Thousands, unless otherwise specified	12 Months Ended
	Jun. 30, 2012
First Trigger
Subsequent Event [Line Items]
Description of the event	We had triggered the first $50,000,000 milestone payment obligation from Janssen under our collaboration and license agreement as a result of the enrollment of a fifth patient in our international Phase III randomized, multicenter, open-label clinical trial of ibrutinib versus ofatumumab for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).
Milestone payment obligations due based upon triggers	$ 50,000
Date of trigger	Aug. 01, 2012
Second Trigger
Subsequent Event [Line Items]
Description of the event	On August 20, 2012, we announced that we had triggered the second $50,000,000 milestone payment obligation from Janssen under the collaboration and license agreement as a result of the enrollment of a fifth patient in our single-arm, multi-center Phase II trial of ibrutinib in patients with relapsed or refractory mantle cell lymphoma (MCL).
Milestone payment obligations due based upon triggers	$ 50,000
Date of trigger	Aug. 20, 2012